Insights Into Metastatic Colorectal Cancer (mCRC) (Arizona)
Expert analysis on treatment approaches, shared decision-making, and emerging options for refractory mCRC from academic and community oncology practices in Arizona.
Tempe, AZ — October 4, 2025
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Scottsdale, AZ, USA
Example Report
Start discovering the insights.
More Information
- Casa Grande, AZ
- Chandler, AZ
- Gilbert, AZ
- Glendale, AZ
- Mesa, AZ
- Phoenix, AZ
- Scottsdale, AZ
Report Snapshot
- Explore key differences in physicians’ approaches between academic and community-based settings
- Understand how clinical factors and patient characteristics influence choices for third- and fourth-line treatments in refractory mCRC
- Gauge physician awareness and adoption of novel options like fruquintinib, and gain insights into shared decision-making and practice drivers
Geographic Representation and Content Development
- Data collection was conducted through the utilization of an audience response system and facilitated moderated discussion
- The experts included 15 community oncologists from Arizona